欧洲皮肤癌诊断市场预测至 2028 年 - COVID-19 影响和按类型（黑色素瘤和非黑色素瘤）和筛查类型（血液测试、皮肤镜检查、影像测试、淋巴结活检和皮肤活检）进行的区域分析
No. of Pages: 108 | Report Code: TIPRE00029077 | Category: Life Sciences
No. of Pages: 108 | Report Code: TIPRE00029077 | Category: Life Sciences
2021 年 12 月，Foundation Medicine， Inc. 的 FoundationOneCDx 获得 FDA 批准。 FoundationOneCDx 是下一代基于测序的体外诊断设备。它是 FDA 批准的当前和未来黑色素瘤治疗药物。它是通过针对 BRAFV600E 突变的 BRAF 抑制剂单一疗法和针对 BRAFV600E 或 V600K 突变的 BRAF/MEK 抑制剂联合疗法实现的。它被认为是简化肿瘤学家决策的重要一步。癌症诊断公司的此类创新正在推动皮肤癌诊断市场的增长。
凭借新功能和技术，供应商吸引了新客户并扩大他们在新兴市场的足迹。这一因素正在推动皮肤癌诊断市场以显着的复合年增长率增长。
皮肤癌诊断市场细分为以下类型和筛选类型。根据类型，市场分为黑色素瘤和非黑色素瘤。根据筛查类型，市场分为皮肤活检、皮肤镜检查、淋巴结活检、影像学检查和血液检查。根据国家/地区，市场分为德国、英国、法国、西班牙、意大利和欧洲其他地区。
SkylineDx BV； AMLo 生物科学有限公司； DermLite 有限责任公司；生物梅里埃公司； NeraCare GmbH、F. Hoffmann-La Roche Ltd.；和 Michelson Diagnostics Ltd. 是欧洲皮肤癌诊断市场的领先公司之一。
Strategic insights for Europe Skin Cancer Diagnostics involve closely monitoring industry trends, consumer behaviours, and competitor actions to identify opportunities for growth. By leveraging data analytics, businesses can anticipate market shifts and make informed decisions that align with evolving customer needs. Understanding these dynamics helps companies adjust their strategies proactively, enhance customer engagement, and strengthen their competitive edge. Building strong relationships with stakeholders and staying agile in response to changes ensures long-term success in any market.
| Report Attribute | Details |
|---|---|
| Market size in 2021 | US$ 886.6 Million |
| Market Size by 2028 | US$ 1,375.9 Million |
| Global CAGR (2021 - 2028) | 6.5% |
| Historical Data | 2019-2020 |
| Forecast period | 2022-2028 |
| Segments Covered |
By 类型
|
| Regions and Countries Covered | 欧洲
|
| Market leaders and key company profiles |
The regional scope of Europe Skin Cancer Diagnostics refers to the geographical area in which a business operates and competes. Understanding regional nuances, such as local consumer preferences, economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved regions or adapting their offerings to meet regional demands. A clear regional focus allows for more effective resource allocation, targeted marketing, and better positioning against local competitors, ultimately driving growth in those specific areas.
The Europe Skin Cancer Diagnostics Market is valued at US$ 886.6 Million in 2021, it is projected to reach US$ 1,375.9 Million by 2028.
As per our report Europe Skin Cancer Diagnostics Market, the market size is valued at US$ 886.6 Million in 2021, projecting it to reach US$ 1,375.9 Million by 2028. This translates to a CAGR of approximately 6.5% during the forecast period.
The Europe Skin Cancer Diagnostics Market report typically cover these key segments-
The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the Europe Skin Cancer Diagnostics Market report:
The Europe Skin Cancer Diagnostics Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include:
The Europe Skin Cancer Diagnostics Market report is valuable for diverse stakeholders, including:
Essentially, anyone involved in or considering involvement in the Europe Skin Cancer Diagnostics Market value chain can benefit from the information contained in a comprehensive market report.
Office No. 1011, First floor, Farena Corporate Park, Magarpatta-Mundhwa road, Pune - 411028, Maharashtra, India
US:+16467917070
sales@businessmarketinsights.com
Get Free Sample For Europe Skin Cancer Diagnostics Market
